WallStreetZenWallStreetZen

NASDAQ: URGN
Urogen Pharma Ltd Stock Forecast, Predictions & Price Target

Analyst price target for URGN

Based on 2 analysts offering 12 month price targets for Urogen Pharma Ltd.
Min Forecast
$34.00+136.6%
Avg Forecast
$44.00+206.19%
Max Forecast
$54.00+275.78%

Should I buy or sell URGN stock?

Based on 2 analysts offering ratings for Urogen Pharma Ltd.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their URGN stock forecasts and price targets.

URGN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-18
lockedlocked$00.00+00.00%2024-03-15

1 of 1

Forecast return on equity

Is URGN forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.81%

Forecast return on assets

Is URGN forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

URGN revenue forecast

What is URGN's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$99.4M+20.14%
Avg 2 year Forecast
$172.2M+108.14%
Avg 3 year Forecast
$278.1M+236.22%
URGN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

URGN revenue growth forecast

How is URGN forecast to perform vs Biotechnology companies and vs the US market?
Company
48.09%
Industry
37.64%
Market
10.1%
URGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
URGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

URGN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
URGN$14.37$44.00+206.19%Buy
AVBP$15.90$30.67+92.87%Strong Buy
ALEC$5.17$19.25+272.34%Strong Buy
KALV$11.44$29.50+157.87%Buy
FATE$4.78$7.13+49.06%Hold

Urogen Pharma Stock Forecast FAQ

Is Urogen Pharma Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: URGN) stock is to Buy URGN stock.

Out of 2 analysts, 0 (0%) are recommending URGN as a Strong Buy, 2 (100%) are recommending URGN as a Buy, 0 (0%) are recommending URGN as a Hold, 0 (0%) are recommending URGN as a Sell, and 0 (0%) are recommending URGN as a Strong Sell.

If you're new to stock investing, here's how to buy Urogen Pharma stock.

What is URGN's revenue growth forecast for 2024-2026?

(NASDAQ: URGN) Urogen Pharma's forecast annual revenue growth rate of 48.09% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.64%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.1%.

Urogen Pharma's revenue in 2024 is $82,713,000.On average, 2 Wall Street analysts forecast URGN's revenue for 2024 to be $3,390,882,396, with the lowest URGN revenue forecast at $3,378,086,613, and the highest URGN revenue forecast at $3,403,678,178. On average, 2 Wall Street analysts forecast URGN's revenue for 2025 to be $5,874,458,498, with the lowest URGN revenue forecast at $5,578,961,225, and the highest URGN revenue forecast at $6,169,955,771.

In 2026, URGN is forecast to generate $9,489,352,395 in revenue, with the lowest revenue forecast at $9,489,352,395 and the highest revenue forecast at $9,489,352,395.

What is URGN's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: URGN) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is URGN's Price Target?

According to 2 Wall Street analysts that have issued a 1 year URGN price target, the average URGN price target is $44.00, with the highest URGN stock price forecast at $54.00 and the lowest URGN stock price forecast at $34.00.

On average, Wall Street analysts predict that Urogen Pharma's share price could reach $44.00 by Apr 18, 2025. The average Urogen Pharma stock price prediction forecasts a potential upside of 206.19% from the current URGN share price of $14.37.

What is URGN's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: URGN) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.